資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34155
|
| 標題: | Flavokawain B and Doxorubicin Work Synergistically to Impede the Propagation of Gastric Cancer Cells via ROS-Mediated Apoptosis and Autophagy Pathways |
| 作者: | Hseu, You-Cheng
Lin, Ruei-Wan
Shen, Yi-Chun
Lin, Kai-Yuan
Liao, Jiunn-Wang
Thiyagarajan, Varadharajan
Yang, Hsin-Ling |
| 貢獻者: | China Med Univ, Coll Pharm, Dept Cosmeceut
Asia Univ, Dept Hlth & Nutr Biotechnol
China Med Univ, Chinese Med Res Ctr
China Med Univ, Res Ctr Chinese Herbal Med
China Med Univ, Inst Nutr
Chi Mei Med Ctr, Dept Med Res
Chia Nan Univ Pharm & Sci, Dept Biotechnol
Natl Chung Hsing Univ, Grad Inst Vet Pathol |
| 關鍵字: | flavokawain B
doxorubicin
apoptosis
autophagy
ROS |
| 日期: | 2020 |
| 上傳時間: | 2022-11-18 11:26:18 (UTC+8) |
| 出版者: | Mdpi |
| 摘要: | Simple Summary Among various kinds of treatment strategies for cancers, combination therapy has attracted significant attention due to its beneficial effects than the individual effects of the same compounds. Based on this idea, this study has investigated the synergistic effects of combination treatment of a natural anti-cancer agent flavokawain B (FKB) and a chemotherapeutic agent Doxorubicin on human gastric cancer cells and the underlying molecular mechanisms were deciphered through in vitro and in vivo approaches. Experimental data obtained in this study provided promising application prospects of FKB + Doxrubicin combination treatment in human gastric cancer cells. Chalcone flavokawain B (FKB) possesses a chemopreventive and anti-cancer activity. Doxorubicin is a chemotherapeutic DNA intercalating agent widely used in malignancy treatment. The present study investigated whether synergistic effects exist between the combination of FKB (1.25-5 mu g/mL) and doxorubicin (0.5 mu g/mL) on the apoptosis and autophagy in human gastric cancer (AGS) cells, and the possible in vitro and in vivo mechanisms. The MTT assay measured cell viability. Various apoptotic-, autophagy-associated protein expression was determined by the Western blot technique. FKB+doxorubicin synergy was estimated by the Chou-Talalay combination index (CI) method. In vivo studies were performed on BALB/c mice. Results showed that compared to FKB/doxorubicin treatments, low doses of FKB+doxorubicin suppressed AGS cell growth. FKB potentiated doxorubicin-induced DNA fragmentation, apoptotic cell death, and enhanced doxorubicin-mediated mitochondrial, death receptor pathways. FKB+doxorubicin activated increased LC3-II accumulation, p62/SQSTM1 expression, and AVO formation as compared to the FKB/doxorubicin alone treatments indicating autophagy in these cells. The death mechanism in FKB+doxorubicin-treated AGS cells is due to the activation of autophagy. FKB+doxorubicin-mediated dysregulated Bax/Bcl-2, Beclin-1/Bcl-2 ratios suggested apoptosis, autophagy induction in AGS cells. FKB+doxorubicin-induced LC3-II/AVOs downregulation was suppressed due to an apoptotic inhibitor Z-VAD-FMK. Whereas, 3-methyladenine/chloroquine weakened FKB+doxorubicin-induced apoptosis (decreased DNA fragmentation/caspase-3). Activation of ERK/JNK may be involved in FKB+doxorubicin-induced apoptosis and autophagy. FKB+doxorubicin-triggered ROS generation, but NAC attenuated FKB+doxorubicin-induced autophagic (LC3 accumulation) and apoptotic (caspase-3 activation and PARP cleavage) cell death. FKB+doxorubicin blocked gastric cancer cell xenografts in nude mice in vivo as compared to FKB/doxorubicin alone treatments. FKB and doxorubicin wielded synergistic anti-tumor effects in gastric cancer cells and is a promising therapeutic approach. |
| 關聯: | Cancers, v.12, n.9, pp.26 |
| 顯示於類別: | [生物科技系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.3390cancers12092475.pdf | | 9099Kb | Adobe PDF | 142 | 檢視/開啟 | | index.html | | 0Kb | HTML | 466 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
